Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
PHASE3CompletedINTERVENTIONAL
Enrollment
262
Participants
Timeline
Start Date
August 1, 2016
Primary Completion Date
September 4, 2018
Study Completion Date
September 8, 2022
Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL
pembrolizumab
DRUG
carboplatin
DRUG
paclitaxel
DRUG
pemetrexed
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT03850444 - Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study | Biotech Hunter | Biotech Hunter